The 36-month beta value for ALXO is also noteworthy at 1.01. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALXO is 33.63M, and at present, short sellers hold a 19.17% of that float. The average trading volume of ALXO on March 06, 2025 was 1.03M shares.
ALXO) stock’s latest price update
The stock price of Alx Oncology Holdings Inc (NASDAQ: ALXO) has jumped by 27.84 compared to previous close of 1.04. Despite this, the company has seen a gain of 24.25% in its stock price over the last five trading days. globenewswire.com reported 2025-03-05 that Event to include updates on ongoing evorpacept clinical development program and introduction of clinical trials in breast and colorectal cancers Advancing novel EGFR-targeted antibody-drug conjugate (ADC) candidate, ALX2004, into clinical-stage development with IND submission planned for Q1 2025 Company implements strategic prioritization, resource optimizations and reductions to extend cash runway into Q4 2026 Webcast featuring company leadership and external key opinion leaders to take place today at 6:00 a.m. PT/9:00 a.m.
ALXO’s Market Performance
ALXO’s stock has risen by 24.25% in the past week, with a monthly rise of 3.06% and a quarterly drop of -19.91%. The volatility ratio for the week is 8.51% while the volatility levels for the last 30 days are 7.94% for Alx Oncology Holdings Inc The simple moving average for the last 20 days is 20.98% for ALXO’s stock, with a simple moving average of -60.30% for the last 200 days.
Analysts’ Opinion of ALXO
Jefferies, on the other hand, stated in their research note that they expect to see ALXO reach a price target of $2, previously predicting the price at $12. The rating they have provided for ALXO stocks is “Hold” according to the report published on December 19th, 2024.
Stifel gave a rating of “Hold” to ALXO, setting the target price at $14 in the report published on March 08th of the previous year.
ALXO Trading at -5.86% from the 50-Day Moving Average
After a stumble in the market that brought ALXO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.54% of loss for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 8.51%, as shares surge +7.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.14% lower at present.
During the last 5 trading sessions, ALXO rose by +24.30%, which changed the moving average for the period of 200-days by -90.93% in comparison to the 20-day moving average, which settled at $1.0990. In addition, Alx Oncology Holdings Inc saw -20.39% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALXO starting from Pinto Shelly, who sale 550 shares at the price of $1.15 back on Feb 19 ’25. After this action, Pinto Shelly now owns 87,352 shares of Alx Oncology Holdings Inc, valued at $633 using the latest closing price.
Pons Jaume, the PRESIDENT & CSO of Alx Oncology Holdings Inc, sale 1,326 shares at $1.15 during a trade that took place back on Feb 19 ’25, which means that Pons Jaume is holding 579,388 shares at $1,525 based on the most recent closing price.
Stock Fundamentals for ALXO
Current profitability levels for the company are sitting at:
- -64.47 for the present operating margin
- 0.74 for the gross margin
The net margin for Alx Oncology Holdings Inc stands at -60.95. The total capital return value is set at -1.04. Equity return is now at value -98.94, with -74.50 for asset returns.
Based on Alx Oncology Holdings Inc (ALXO), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -13.17. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -93.11.
Currently, EBITDA for the company is -158.4 million with net debt to EBITDA at 0.04. When we switch over and look at the enterprise to sales, we see a ratio of 27.03. The receivables turnover for the company is 2.1for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.82.
Conclusion
In summary, Alx Oncology Holdings Inc (ALXO) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
